Cytopacx was founded in March 2022 by Dr. Yao-Chang Chen, Honorary Professor at the College of Medicine, National Taiwan University; Dr. Yen-Rong Chen, Associate Professor at the Department of Biochemical Science and Technology, National Taiwan University; and Dr. Shu-Hsing Hsu, CEO. The company focuses on developing high-quality medical solutions based on cutting-edge biotechnology, with a particular emphasis on precision and regenerative medicine. Their areas of expertise include disease prevention, neuroregeneration, and tissue repair. Cytopacx is committed to promoting health equity for all and aims to provide the public with superior health products and services. Additionally, they leverage regenerative medical products, such as exosome technology, to support treatments for neurodegenerative diseases and applications in beauty and skincare.